2000-2004 Publications


  1. Børset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood, 2000 Oct 1;96(7);2528-36. PMID: 11001907
  2. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood, 2000 Aug 15;96(4);1505-11. PMID: 10942398
  3. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 2000 Jun 15;95(12);4008-10. PMID: 10845942
  4. Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, Waage A, Sundan A, Börset M.Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol, 2000 Jun;109(4);815-22. PMID: 10929035
  5. Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Mehta J, Spoon D, Anaissie E, Barlogie B, Munshi N. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant, 2000 Mar;25(5);483-7. PMID: 10713623
  6. Vartivarian SE, Anaissie EJ, Kiwan EN, Papadakis KA. The clinical spectrum of stenotrophomonas (xanthomonas) maltophilia respiratory infection. Semin Respir Crit Care Med, 2000;21(4);349-55. PMID: 16088746


  1. Anaissie EJ, Kuchar RT, Rex JH, Francesconi A, Kasai M, Müller FM, Lozano-Chiu M, Summerbell RC, Dignani MC, Chanock SJ, Walsh TJ. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis, 2001 Dec 1;33(11);1871-8. PMID: 11692299
  2. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol, 2001 Dec;28(6);577-82. PMID: 11740812
  3. Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne. Clin Infect Dis, 2001 Nov 1;33(9);1546-8.PMID: 11568850
  4. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A, 2001 Sep 25;98(20);11581-6. PMID: 11562486
  5. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G.Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 2001 Sep 1;98(5);1614-5. PMID: 11520815
  6. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol, 2001 Sep;114(4);822-9. PMID: 11564069
  7. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, Tricot G.Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol, 2001 Sep;114(3);600-7. PMID: 11552985
  8. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.Blood, 2001 Jul 15;98(2);492-4. PMID: 11435324
  9. Shaughnessy J Jr, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, Kuehl M. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood, 2001 Jul 1;98(1);217-23. PMID: 11418483
  10. Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G. Thalidomide in the management of multiple myeloma. Semin Hematol, 2001 Jul;38(3);250-9. PMID: 11486313
  11. Shaughnessy JD, Barlogie B. Developmental therapeutics for multiple myeloma–a road map for the future.Semin Hematol, 2001 Jul;38(3);295-7. PMID: 11486318
  12. Barlogie B. Introduction to therapies in multiple myeloma. Semin Hematol, 2001 Jul;38(3);201-2. PMID: 11486306
  13. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G, Aniassie E. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood, 2001 May 1;97(9);2574-9. PMID: 11313244
  14. Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol, 2001 Apr;38(2 Suppl 3);21-7. PMID: 11309705
  15. Avva R, Vanhemert RL, Barlogie B, Munshi N, Angtuaco EJ. CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. AJNR Am J Neuroradiol, 2001 Apr;22(4);781-5. PMID: 11290500
  16. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood, 2001 Mar 15;97(6);1750-5. PMID: 11238117
  17. Lim SH, Badros A, Lue C, Barlogie B. Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma. Cancer, 2001 Mar 1;91(5);900-8. PMID: 11251941
  18. Wilson CS, Butch AW, Lai R, Medeiros LJ, Sawyer JR, Barlogie B, McCourty A, Kelly K, Brynes RK. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br J Haematol, 2001 Mar;112(3);776-82.PMID: 11260083
  19. Chiriva-Internati M, Du J, Cannon M, Barlogie B, Yi Q. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway. Br J Haematol, 2001 Feb;112(2);410-20. PMID: 11167840
  20. Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol, 2001 Jan;112(1);242-7. PMID: 11167811
  21. Sawyer JR, Lukacs JL, Thomas EL, Swanson CM, Goosen LS, Sammartino G, Gilliland JC, Munshi NC, Tricot G, Shaughnessy JD Jr, Barlogie B. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol, 2001 Jan;112(1);167-74.PMID: 11167798


  1. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood, 2002 Dec 1;100(12);4162-8. PMID: 12393672
  2. Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant, 2002 Dec;30(12);873-8. PMID: 12476279
  3. Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol, 2002 Dec;29(6 Suppl 17);26-33. PMID: 12520482
  4. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Mahfouz TH, Rex JH, Summerbell RC, Walsh TJ. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis, 2002 Oct 15;35(8);E86-8. PMID: 12355397
  5. Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, Tricot G. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol, 2002 Oct;119(1);164-8.PMID: 12358921
  6. Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia, 2002 Sep;16(9);1835-7. PMID: 12200700
  7. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol, 2002 Sep;118(4);1041-7. PMID: 12199783
  8. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, Rème T, Legouffe E, Rossi JF, Shaughnessy J Jr, Ørntoft TF, Klein B. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood, 2002 Aug 15;100(4);1113-22. PMID: 12149187
  9. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood, 2002 Aug 15;100(4);1168-71. PMID: 12149193
  10. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood, 2002 Aug 1;100(3);961-5. PMID: 12130509
  11. Min R, Li Z, Epstein J, Barlogie B, Yi Q. Beta(2)-microglobulin as a negative growth regulator of myeloma cells. Br J Haematol, 2002 Aug;118(2);495-505. PMID: 12139738
  12. Shaughnessy JD Jr, Barlogie B. Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myeloma. Int J Hematol, 2002 Aug;76 Suppl 259-64. PMID: 12430902
  13. Barlogie B Jr, Shaughnessy JD. Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH. Int J Hematol, 2002 Aug;76 Suppl 1337-9. PMID: 12430877
  14. Gubbins PO, Penzak SR, Polston S, McConnell SA, Anaissie E. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients.Pharmacotherapy, 2002 Aug;22(8);961-71. PMID: 12173799
  15. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 2002 Jul 15;100(2);610-7. PMID: 12091355
  16. Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med, 2002 Jul 8;162(13);1483-92. PMID: 12090885
  17. Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma, 2002 Jun;43(6);1267-71. PMID: 12152995
  18. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood, 2002 May 1;99(9);3280-5. PMID: 11964294
  19. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood, 2002 May 1;99(9);3163-8. PMID: 11964279
  20. Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma.Br J Haematol, 2002 May;117(2);297-305. PMID: 11972511
  21. Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med, 2002 Apr 1;112(5);412-3. PMID: 11904117
  22. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis, 2002 Apr;13(3);187-92. PMID: 11943931
  23. Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol, 2002 Apr;117(1);103-8. PMID: 11918539
  24. Anaissie EJ, Stratton SL, Dignani MC, Summerbell RC, Rex JH, Monson TP, Spencer T, Kasai M, Francesconi A, Walsh TJ. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis, 2002 Mar 15;34(6);780-9. PMID: 11850861
  25. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G.Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol, 2002 Mar 1;20(5);1295-303. PMID: 11870172
  26. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 2002 Mar 1;99(5);1745-57. PMID: 11861292
  27. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol, 2002 Feb;116(2);278-90. PMID: 11841428
  28. Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, Barlogie B, Cottler-Fox M. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion, 2002 Feb;42(2);205-9. PMID: 11896336
  29. Weick JK, Crowley JJ, Hussein MA, Moore DF, Barlogie B, . The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study. Invest New Drugs, 2002 Feb;20(1);117-21. PMID: 12003187
  30. Bumm K, Zheng M, Bailey C, Zhan F, Chiriva-Internati M, Eddlemon P, Terry J, Barlogie B, Shaughnessy JD Jr.CGO: utilizing and integrating gene expression microarray data in clinical research and data management.Bioinformatics, 2002 Feb;18(2);327-8. PMID: 11847084
  31. Khassawneh BY, White P Jr, Anaissie EJ, Barlogie B, Hiller FC. Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation. Chest, 2002 Jan;121(1);185-8. PMID: 11796449
  32. Ornstein DL, Ririe DW, Shaughnessy PJ, Neuhauser T, Bee C. Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation. Bone Marrow Transplant, 2002 Jan;29(1);71-4. PMID: 11840148
  33. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol, 2002 Jan;116(1);211-7. PMID: 11841419
  34. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology Am Soc Hematol Educ Program, 2002;214-40. PMID: 12446425


  1. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 2003 Dec 25;349(26);2483-94. PMID: 14695408
  2. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res, 2003 Dec 15;63(24);8749-56. PMID: 14695190
  3. Xie J, Qian J, Wang S, Freeman ME 3rd, Epstein J, Yi Q. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J Immunol, 2003 Nov 1;171(9);4792-800. PMID: 14568957
  4. Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL.Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood, 2003 Nov 1;102(9);3100-7. PMID: 12855576
  5. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol, 2003 Nov;123(3);484-9. PMID: 14617011
  6. Barlogie B. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol, 2003 Oct;40(4 Suppl 4);33-8. PMID: 15015894
  7. Zhan F, Barlogie B, Shaughnessy J Jr. Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling. Semin Hematol, 2003 Oct;40(4);308-20. PMID: 14582081
  8. Batchu RB, Moreno AM, Szmania S, Gupta SK, Zhan F, Rosen N, Kozlowski M, Spencer T, Spagnoli GC, Shaughnessy J, Barlogie B, Tricot G, van Rhee F. High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector. Hum Gene Ther, 2003 Sep 20;14(14);1333-45. PMID: 14503968
  9. Sherman AC, Coleman EA, Griffith K, Simonton S, Hine RJ, Cromer J, Latif U, Farley H, Garcia R, Anaissie EJ. Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation. Support Care Cancer, 2003 Sep;11(9);568-74. PMID: 12827482
  10. Shaughnessy J Jr. Primer on medical genomics. Part IX: scientific and clinical applications of DNA microarrays–multiple myeloma as a disease model. Mayo Clin Proc, 2003 Sep;78(9);1098-109. PMID: 12962165
  11. Zent CS, Zhan F, Schichman SA, Bumm KH, Lin P, Chen JB, Shaughnessy JD. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res, 2003 Sep;27(9);765-74. PMID: 12804633
  12. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ, . A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol, 2003 Aug;122(3);441-50. PMID: 12877671
  13. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol, 2003 Aug;122(3);430-40. PMID: 12877670
  14. Shaughnessy JD Jr, Barlogie B. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling. Immunol Rev, 2003 Aug;194140-63. PMID: 12846813
  15. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs, 2003 Aug;4(8);974-90. PMID: 14508882
  16. Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, Barlogie B, Shaughnessy JD Jr, Stewart AK. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood, 2003 Jul 15;102(2);772-3. PMID: 12835230
  17. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G.DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol, 2003 Jul 15;21(14);2732-9. PMID: 12860952
  18. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 2003 Jun 26;348(26);2609-17. PMID: 12826635
  19. Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MA. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.Blood, 2003 Jun 15;101(12);4982-9. PMID: 12609839
  20. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost, 2003 Jun;29(3);275-82. PMID: 12888931
  21. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.Clin Lymphoma, 2003 Jun;4(1);32-5. PMID: 12837152
  22. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B.Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood, 2003 May 15;101(10);3849-56. PMID: 12531801
  23. Xie J, Wang Y, Freeman ME 3rd, Barlogie B, Yi Q. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood, 2003 May 15;101(10);4005-12. PMID: 12531797
  24. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Summerbell RC, Rex JH, Monson TP, Walsh TJ. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood, 2003 Apr 1;101(7);2542-6. PMID: 12468437
  25. Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, Smit JW, Zhan F, Shaughnessy J Jr, Bos NA. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol, 2003 Apr;121(1);36-43. PMID: 12670329
  26. Shaughnessy JD Jr. Global gene expression profiling in the study of multiple myeloma. Int J Hematol, 2003 Apr;77(3);213-25. PMID: 12731663
  27. Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom’s macroglobulinemia. Semin Oncol, 2003 Apr;30(2);282-5. PMID: 12720153
  28. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood, 2003 Mar 15;101(6);2374-6. PMID: 12433679
  29. Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Infection–an underappreciated cause of bone pain in multiple myeloma. Br J Haematol, 2003 Mar;120(6);1047-50. PMID: 12648075
  30. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol, 2003 Mar;45(3);227-44. PMID: 12633837
  31. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood, 2003 Feb 1;101(3);1128-40. PMID: 12393520
  32. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol, 2003 Feb;120(3);413-23. PMID: 12580955
  33. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol, 2003 Jan;31(1);73-80.PMID: 12543109
  34. Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol, 2003 Jan;120(1);44-52. PMID: 12492575
  35. Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma.Hematol J, 2003;4(5);310-4. PMID: 14502254
  36. Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program, 2003;248-78. PMID: 14633785


  1. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res, 2004 Dec 15;10(24);8301-8. PMID: 15623606
  2. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia, 2004 Nov;18(11);1891-7. PMID: 15385929
  3. Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol, 2004 Oct;17(10);1217-22. PMID: 15195108
  4. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol, 2004 Oct;127(2);165-72. PMID: 15461622
  5. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol, 2004 Sep;126(5);715-21. PMID: 15327525
  6. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J Jr, Reiman T. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood, 2004 Aug 15;104(4);1151-8. PMID: 15105292
  7. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med, 2004 Aug;128(8);875-9. PMID: 15270616
  8. Miceli MH, Jones Jackson LB, Walker RC, Talamo G, Barlogie B, Anaissie EJ. Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun, 2004 Aug;25(8);813-8. PMID: 15266176
  9. Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TR, Shaughnessy J Jr. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol, 2004 Jul;126(1);72-6. PMID: 15198734
  10. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol, 2004 May 15;22(10);1857-63. PMID: 15111617
  11. Miceli M, Atoui R, Walker R, Mahfouz T, Mirza N, Diaz J, Tricot G, Barlogie B, Anaissie E. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol, 2004 May 15;22(10);1949-56. PMID: 15143089
  12. Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N, Shaughnessy J Jr, Klein B. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br J Haematol, 2004 May;125(3);373-82. PMID: 15086420
  13. Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? Lancet Infect Dis, 2004 May;4(5);278-86. PMID: 15120344
  14. Fahdi IE, Gaddam V, Saucedo JF, Kishan CV, Vyas K, Deneke MG, Razek H, Thorn B, Bissett JK, Anaissie EJ, Anaisse E, Barlogie B, Mehta JL. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol, 2004 Apr 15;93(8);1052-5. PMID: 15081457
  15. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant, 2004 Apr;33(8);823-8. PMID: 14767499
  16. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology, 2004 Apr;231(1);11-23. PMID: 14990813
  17. Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol, 2004 Apr;125(1);24-30. PMID: 15015964
  18. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res, 2004 Mar 15;64(6);2016-23.PMID: 15026338
  19. Anaissie EJ, Mahfouz TH, Aslan T, Pouli A, Desikan R, Fassas A, Barlogie B. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood, 2004 Mar 1;103(5);1611-7. PMID: 14525792
  20. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res, 2004 Feb 15;64(4);1546-58. PMID: 14989251
  21. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.Clin Cancer Res, 2004 Jan 1;10(1 Pt 1);88-95. PMID: 14734456
  22. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of multiple myeloma. Blood, 2004 Jan 1;103(1);20-32. PMID: 12969978
  23. Hardin J, Waddell M, Page CD, Zhan F, Barlogie B, Shaughnessy J, Crowley JJ. Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma. Stat Appl Genet Mol Biol, 2004;3Article10. PMID: 16646788
  24. Harousseau JL, Shaughnessy J Jr, Richardson P. Multiple myeloma. Hematology Am Soc Hematol Educ Program, 2004;237-56. PMID: 15561686